Juvaris Biotherapeutics, Inc.

Burlingame, CA 94010

SBIR Award Summary

Total Number of Awards 9
Total Value of Awards $2.97MM
First Award Date 07/01/04
Most Recent Award Date 09/25/08

Key Personnel

Last Name Name Awards Contact
Fairman Jeff C Fairman 7
Warner John F Warner 2

9 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/25/08 - 08/31/10

DESCRIPTION (provided by applicant): Approximately 350 million people worldwide are chronic carriers of hepatitis B virus (HBV) and more than half of the hepatocellular carcinoma (HCC) cases worldwide are attributed to chronic HBV infection. As HCC has a high mortality rate and current treatment options are remarkably limited, there is an urgent...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 09/01/07 - 02/28/09

DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel immune stimulant that can be used to elicit non-specific protection against pathogenic microorganisms that might be deployed in bioterrorist attacks. The product, comprised of cationic liposome-plasmid DNA complexes (CLDC), is an extrem...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/01/07 - 02/29/08

DESCRIPTION (provided by applicant): The overall purpose of this proposal is to determine the level of innate and adaptive immune activation (i.e., anti-viral Th1 cytokines, antibody and cellular immune responses) induced by cationic lipid-DNA (non-coding) complexes (CLDC) combined with whole-inactivated Simian Immunodeficiency Virus (SIV) virio...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 02/01/07 - 07/31/08

DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/22/06 - 02/29/08

DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel vaccine for Acute Myelogenous Leukemia. This product, cationic lipid-DNA complexes (CLDC), is effective via multiple administration routes in broadly stimulating the innate and adaptive immune system and serving as a potent biologic adj...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 09/01/06 - 08/31/07

DESCRIPTION (provided by applicant): The overall purpose of this project is to investigate and develop a novel immune stimulant that can be used to elicit non-specific protection against pathogenic microorganisms that might be deployed in bioterrorist attacks. The product, comprised of cationic liposome-plasmid DNA complexes (CLDC), is an extrem...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 03/15/06 - 02/28/07

DESCRIPTION (provided by applicant): The overall purpose of this proposal is to determine the level of innate and adaptive immune activation (i.e., anti-viral Th1 cytokines, antibody and cellular immune responses) induced by cationic lipid-DNA (non-coding) complexes (CLDC) combined with whole-inactivated Simian Immunodeficiency Virus (SIV) virio...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 02/01/06 - 01/31/07

DESCRIPTION (provided by applicant): Influenza A (fluA) infection causes annual substantial morbidity and mortality worldwide, particularly for infants, the elderly, and the immuncompromised. FluA mainly replicates in the respiratory tract, with virulent strains also disseminating to other tissues, such as the central nervous system. A growing c...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/04 - 12/31/05

DESCRIPTION (provided by applicant): Juarez BioTherapeutics is developing and characterizing a unique adjuvant and stimulant of innate immunity based on the complexation of a cationic lipid carrier and non-coding DNA (CLDC). The product is effective via multiple routes including parenteral, respiratory and oral. The combination of the lipid-bas...